The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. - Wikidata - wikimedia - TriplyDB

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

http://www.wikidata.org/entity/Q37462829

about

Immunoregulatory functions of immune complexes in vaccine and therapy Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.Receptor binding domain based HIV vaccines.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.Exosomal cancer immunotherapy is independent of MHC molecules on exosomes.Fcγ receptor pathways during active and passive immunization.Immunization with Immune Complexes Modulates the Fine Specificity of Antibody Responses to a Flavivirus Antigen.An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.Recombinant immune complexes as versatile and potent vaccines.Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Fcγ Receptor Function and the Design of Vaccination Strategies.Host- and pathogen-derived adjuvant coatings on protein nanoparticle vaccines.Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines

P2860

Q26738396-3EB1FA44-73C4-4A1F-8433-18E83CBC7186 Q27468870-2FE3A0D7-C704-4C72-A0AF-09E40553FD63 Q30355763-015FDDFC-4132-4358-A8DF-6D11B8A4E249 Q33683203-4692859F-14D9-4FBC-AA56-F02267A9187F Q34128200-FC56FB34-4EC7-440A-89A1-F2CF6EF39795 Q34694812-7CB21B12-B10E-4FED-8350-BEA767ACC17E Q34784825-C224A81C-8064-4B63-BCCC-84B190F4CD72 Q35033862-AD66FFA5-8A20-4944-95A5-2880A1DCD5C6 Q35196671-D5544DAF-F1F6-4EF5-88C3-01F44C9D262D Q35893538-79E95B8C-6049-45E5-8566-DE09A51FE3CC Q36157711-95F08B54-4633-4380-BBD6-C86F40365869 Q36736610-9C458870-6988-4895-96BA-468B3134AFCB Q37252952-C3719D65-B2C1-42F6-822F-EDD8826C9CCA Q37419234-7D0E184A-C665-40F1-B588-430AFF746B29 Q37437640-1E0D344E-F56A-4367-B964-D501DD6DB115 Q38615357-6B9A87D2-92B8-4ACC-B8B8-18B885F5ABC0 Q40154194-DF58C2E0-FF69-473A-86F5-C4109BE242EC Q40463159-C074F9CC-CC9D-40D9-800D-3BA3A99006B4 Q41812053-E9266149-B0A2-457D-BBF8-F172FD7B16BF Q42572387-7EF6B0B0-279B-424E-BB75-53E3E9C19AFA Q47110966-1F0CA3AE-2E66-4AFD-BEC6-C87773B28403 Q47945550-00C3F149-2B9F-44C7-94C3-E7FEC6F3FCE5 Q50995525-40FDCE91-CDC0-40EC-A890-DBDD7C1ED025 Q58707657-3E601486-22AF-4E9F-BA16-1948B0244435

P2860

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

http://www.wikidata.org/entity/Q37462829

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@en

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@nl

type

label

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@en

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@nl

prefLabel

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@en

The use of immune complex vacc ...... topes on HIV-1 envelope gp120.

@nl

P1433

Q37462829-59E8C750-F4D2-4D64-901D-7C7BAB83DAB9

P1476

Q37462829-D39308EA-FCF8-4C58-9786-E2A2362258CF

P2093

Q37462829-141B0CF4-65A7-4C3C-86AC-7372BA30702E

Q37462829-173DCDA5-D54E-4434-ABFC-56E750D0F944

Q37462829-490B7FB3-D02F-4BA3-ACFF-F8D303CD39EB

Q37462829-4C172249-01E0-491A-B51A-27C3A00F2BD8

Q37462829-AE0CA1C5-6B78-4D42-BF6A-F22C21045EAD

Q37462829-AFBBD8EB-339D-4633-B934-9BF064953CDF

Q37462829-B5B9CD65-C741-460B-AB72-2E3DBB3D6E3F

P2860

Q37462829-00AB4279-33AB-4D27-854E-ADF10C10CA9F

Q37462829-07861D89-D9DC-470B-AD55-AEDCEFD8476C

Q37462829-1726EEC3-7163-45D0-9BD0-1FE8567F2D52

Q37462829-1CB017AF-95B7-4056-8542-31A6F13899A8

Q37462829-1FDD7B08-DFFD-464D-AF71-4E6BD2307A14

Q37462829-212ECCD0-9E3C-4C95-B9D1-F911FCDBC1D9

Q37462829-226453FB-3FA6-452D-9CF7-BA6A4AAAF35D

Q37462829-2B0CF189-0A8A-4AFA-9EA3-CE6B7D25F7B9

Q37462829-361A4654-8D1C-4A40-8E0E-CA26DC1C1209

Q37462829-37052089-0CAB-4AE3-8F29-CDFF46443358

P304

Q37462829-45C576E3-2A50-467B-8031-E07C822C8C59

P31

Q37462829-E06D6B74-2C28-4A9C-9D32-FB038508758E

P356

Q37462829-163B3959-E61A-40C9-B037-716ECD1CFE69

P407

Q37462829-340FCC63-960C-4048-997E-B957FCEC6366

P433

Q37462829-F4B94AC5-002F-41C7-A8B0-668E369DF72D

P478

Q37462829-774BF762-BBC3-4223-AFB6-601FFEEE1973

P50

Q37462829-5F677CFD-5B37-4035-B3B9-1D111FC31FE3

P577

Q37462829-AE9C99A7-276C-4763-8CD8-8636822E714E

P5875

Q37462829-90C1AEEC-8840-4141-8ACC-38C531B1BB6A

P698

Q37462829-EA601BA7-DACC-4A2B-93A2-F13B4571AC75

P921

Q37462829-7C8EF07D-2697-414D-8E9F-6C048507C242

Q37462829-E2974840-E67E-491D-BC8E-DFD15EAAF82F

P932

Q37462829-D011C6A3-4266-499E-8A4E-DF6C8A3BD7D6

P356

J.VACCINE.2009.10.040

P1433

P1476

The use of immune complex vacc ...... itopes on HIV-1 envelope gp120

@en

P2093

Catarina E Hioe

http://www.w3.org/2001/XMLSchema#string

David N Levy

http://www.w3.org/2001/XMLSchema#string

Jianping Liu

http://www.w3.org/2001/XMLSchema#string

Maria Luisa Visciano

http://www.w3.org/2001/XMLSchema#string

Michael Tuen

http://www.w3.org/2001/XMLSchema#string

Rachel E Simon

http://www.w3.org/2001/XMLSchema#string

Rajnish Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

GP120: target for neutralizing HIV-1 antibodies

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry.

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients.

Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.

Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.

Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction.

Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120

P304

352-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.10.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38057505

http://www.w3.org/2001/XMLSchema#string

P698

19879224

http://www.w3.org/2001/XMLSchema#string

P921

P932

2789659

http://www.w3.org/2001/XMLSchema#string